Help us: Donate
Follow us on:
×

Menu

Back

Tag: Greg Fahy

Greg Fahy
Dr. Greg Fahy, Chief Scientific Officer of Intervene Immune, has recently appeared on The Damage Report, a news and current events show that is part of The Young Turks (TYT) network. Hosts John Iadarola and Brooke Thomas talked with Dr. Fahy about the recent positive results of his company's human clinical trial for thymus rejuvenation....
Un pequeño ensayo clínico, que fue realizado por un equipo de investigadores dirigido por el Dr. Greg Fahy, mostró por primera vez en humanos que revertir la edad biológica puede ser posible. Los resultados del TRIIM fueron divulgados Los investigadores realizaron durante un año el ensayo de Regeneración del Timo, Inmunorrestauración y Mitigación de la...
Greg Fahy at EARD2019
We're continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Dr. Greg Fahy of Intervene Immune gave a presentation about his company's Phase 1 human trials in which the thymus,...
A small clinical trial, which was conducted by a team of researchers led by Dr. Greg Fahy, has shown for the first time in humans that reversing biological age may be possible. The results of TRIIM are in The researchers spent a year running the Thymus Regeneration, Immunorestoration, and Insulin Mitigation (TRIIM) trial, which included...
EARD reception
Ending Age-Related Diseases 2019 is over, and the dust is starting to settle after what can only be described as a hugely successful event for our organization. This was our second year of running a conference, and once more, we focused on the research and investment areas of rejuvenation biotechnology. Totally sold out We wish...
On July 11-12th, we return to the Cooper Union in New York City for our second annual Ending Age-Related Diseases conference, which focuses on the progress in aging research as well as the business side of biotech. We will be bringing you the latest aging research, investment, and business knowledge from some of the top...